Regulation 145 Amendment of regulation 186 (reporting obligations on the licensing authority)I1F1
United Kingdom
In regulation 186—
in paragraph (1), for sub-paragraphs (d) and (e) substitute—
“(d)submit reports of serious suspected adverse reactions in Northern Ireland that it has recorded under regulation 185 in relation to—
(i)a UKMA(NI),
(ii)a UKMA(UK),
(iii)a THR(NI),
(iv)a THR(UK), or
(v)an Article 126a authorisation,
to the EMA before the end of the period of 15 days beginning on the day following the day on which the report was received; and
(e)submit reports of non-serious suspected adverse reactions in Northern Ireland that it has recorded under regulation 185 in relation to—
(i)a UKMA(NI),
(ii)a UKMA(UK),
(iii)a THR(NI),
(iv)a THR(UK), or
(v)an Article 126a authorisation,
to the EMA before the end of the period of 90 days beginning on the day following the day on which the report was received.”;
omit paragraph (4).
Annotations
Textual amendments
- F1
Reg. 145 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 113
Commencement
- I1
Reg. 145 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1